65 research outputs found
Molecular Hydrogen in the FUSE Translucent Lines of Sight: The Full Sample
We report total abundances and related parameters for the full sample of the
FUSE survey of molecular hydrogen in 38 translucent lines of sight. New results
are presented for the "second half" of the survey involving 15 lines of sight
to supplement data for the first 23 lines of sight already published. We assess
the correlations between molecular hydrogen and various extinction parameters
in the full sample, which covers a broader range of conditions than the initial
sample. In particular, we are now able to confirm that many, but not all, lines
of sight with shallow far-UV extinction curves and large values of the
total-to-selective extinction ratio, = / -- characteristic
of larger than average dust grains -- are associated with particularly low
hydrogen molecular fractions (). In the lines of sight with large
, there is in fact a wide range in molecular fractions, despite the
expectation that the larger grains should lead to less H formation.
However, we see specific evidence that the molecular fractions in this
sub-sample are inversely related to the estimated strength of the UV radiation
field and thus the latter factor is more important in this regime. We have
provided an update to previous values of the gas-to-dust ratio, (H)/, based on direct measurements of (H) and (H I).
Although our value is nearly identical to that found with Copernicus data, it
extends the relationship by a factor of 2 in reddening. Finally, as the new
lines of sight generally show low to moderate molecular fractions, we still
find little evidence for single monolithic "translucent clouds" with 1.Comment: 35 pages, 5 tables, 7 figures, accepted for publication in The
Astrophysical Journal Supplements Serie
A New FUSE Survey of Interstellar HD
We have used archival FUSE data to complete a survey of interstellar HD in 41
lines of sight with a wide range of extinctions. This follow up to an earlier
survey was made to further assess the utility of HD as a cosmological probe; to
analyze the HD formation process; and to see what trends with other
interstellar properties were present in the data. We employed the
curve-of-growth method, supported by line profile fitting, to derive accurate
column densities of HD. We find that the N(HD)/2N(H2) ratio is substantially
lower than the atomic D/H ratio and conclude that the molecular ratio has no
bearing on cosmology, because local processes are responsible for the formation
of HD. Based on correlations with E(B-V), H2, CO, and iron depletion, we find
that HD is formed in the densest portion of the clouds; the slope of the
logN(HD)/log(H2) correlation is greater than 1.0, caused by the destruction
rate of HD declining more slowly than that of H2; and, as a sidelight, that the
depletions are density dependent.Comment: 30 pages, 13 figures; Accepted for publication in Ap
A High Signal-to-Noise Ratio Composite Spectrum of Gamma-ray Burst Afterglows
We present a composite spectrum of 60 long duration gamma-ray burst (GRB)
afterglows with redshifts in the range 0.35<z<6.7 observed with low resolution
optical spectra. The composite spectrum covers the wavelength range 700-6600 A
in the rest frame and has a mean signal-to-noise ratio of 150 per 1 A pixel and
reaches a maximum of ~300 in the range 2500-3500 A. Equivalent widths are
measured from metal absorption lines from the Lya line to ~5200 A, and
associated metal and hydrogen lines are identified between the Lyman break and
Lya line. The average transmission within the Lyman forest is consistent with
that found along quasar lines of sight. We find a temporal variation in fine
structure lines when dividing the sample into bursts observed within 2 hours
from their trigger and those observed later. Other lines in the predominantly
neutral gas show variations too, but this is most likely a random effect caused
by weighting of individual strong absorption lines and which mimics a temporal
variation. Bursts characterized with high or low prompt GRB energy release
produce afterglows with similar absorption line strengths, and likewise for
bursts with bright or faint optical afterglows. Bursts defined as dark from
their optical to X-ray spectral index have stronger absorption lines relative
to the optically bright bursts. The composite spectrum has strong CaII and MgII
absorption lines as commonly found in dusty galaxies, however, we find no
evidence for dust or a significant molecular content based on the non-detection
of diffuse interstellar bands. Compared to starburst galaxy spectra, the GRB
composite has much stronger fine structure lines, while metal absorption lines
are weaker.Comment: Accepted for publication in ApJ, 24 page
High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation
Neurofibromatosis type 1 (NF1) is one of the most frequent genetic disorders, affecting 1:3,000 worldwide. Identification of genotype-phenotype correlations is challenging because of the wide range clinical variability, the progressive nature of the disorder, and extreme diversity of the mutational spectrum. We report 136 individuals with a distinct phenotype carrying one of five different NF1 missense mutations affecting p.Arg1809. Patients presented with multiple cafe-au-lait macules (CALM) with or without freckling and Lisch nodules, but no externally visible plexiform neurofibromas or clear cutaneous neurofibromas were found. About 25% of the individuals had Noonan-like features. Pulmonic stenosis and short stature were significantly more prevalent compared with classic cohorts (P<0.0001). Developmental delays and/or learning disabilities were reported in over 50% of patients. Melanocytes cultured from a CALM in a segmental NF1-patient showed two different somatic NF1 mutations, p.Arg1809Cys and a multi-exon deletion, providing genetic evidence that p.Arg1809Cys is a loss-of-function mutation in the melanocytes and causes a pigmentary phenotype. Constitutional missense mutations at p.Arg1809 affect 1.23% of unrelated NF1 probands in the UAB cohort, therefore this specific NF1 genotype-phenotype correlation will affect counseling and management of a significant number of patients
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation: HUMAN MUTATION
Neurofibromatosis type 1 (NF1) is one of the most frequent genetic disorders, affecting 1:3,000 worldwide. Identification of genotype–phenotype correlations is challenging because of the wide range clinical variability, the progressive nature of the disorder, and extreme diversity of the mutational spectrum. We report 136 individuals with a distinct phenotype carrying one of five different NF1 missense mutations affecting p.Arg1809. Patients presented with multiple café‐au‐lait macules (CALM) with or without freckling and Lisch nodules, but no externally visible plexiform neurofibromas or clear cutaneous neurofibromas were found. About 25% of the individuals had Noonan‐like features. Pulmonic stenosis and short stature were significantly more prevalent compared with classic cohorts (P < 0.0001). Developmental delays and/or learning disabilities were reported in over 50% of patients. Melanocytes cultured from a CALM in a segmental NF1‐patient showed two different somatic NF1 mutations, p.Arg1809Cys and a multi‐exon deletion, providing genetic evidence that p.Arg1809Cys is a loss‐of‐function mutation in the melanocytes and causes a pigmentary phenotype. Constitutional missense mutations at p.Arg1809 affect 1.23% of unrelated NF1 probands in the UAB cohort, therefore this specific NF1 genotype–phenotype correlation will affect counseling and management of a significant number of patients
The Physics of the B Factories
This work is on the Physics of the B Factories. Part A of this book contains a brief description of the SLAC and KEK B Factories as well as their detectors, BaBar and Belle, and data taking related issues. Part B discusses tools and methods used by the experiments in order to obtain results. The results themselves can be found in Part C
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
- …